AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06280937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearing a tie
Description: Individuals in the study group will be asked to wear a tie during one office working day.
Study NCT06337994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine Hydrochloride
Description: Memantine was added to each patient's current medication, with the initial dosage of 5 mg/day (once daily). The dosage was then increased to 10 mg/day after a week and maintained till the end of the study. In the case of intolerance to this increase, the dosage was flexibly adjusted according to the condition of the patient.
Study NCT05228704 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: activities in the Botanical Garden or in urban
Description: activities in the Taipei Botanical Garden or in Urban
Study NCT05228704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activities in the Botanical Garden or in urban
Description: activities in the Taipei Botanical Garden or in Urban
Study NCT05739253 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter aortic valve replacement
Description: All patients undergo transfemoral transcatheter aortic valve replacement for aortic stenosis
Study NCT04930419 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Videolaryngoscopy group
Description: Tracheal intubation will be performed using Videolaryngoscope in first intention and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
Study NCT04930419 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Direct laryngoscopy group
Description: Tracheal intubation will be performed using Direct laryngoscopy with Macintosh blades in first intention. and will be performed using standard pre-hospital intubation procedures : preoxygenation before intubation, maintenance of oxygenation throughout procedure, standard sedation technique (using rapid sequence intubation (RSI)), correct position confirmation using a capnogram and conditioning (hemodynamic monitoring, respirator settings, securing). If the first attempt at intubation is unsuccessful, further management will be left to the discretion of the clinician according to the procedures and algorithm of usual standard care
Study NCT05702723 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart-3RP
Description: 9 sessions of mind-body group treatment program via Zoom platform.
Study NCT05702723 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: 14-week group-based, online support group through CancerCare.org.
Study NCT05643638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)
Description: Cymerus MSCs are derived from iPSCs using the proprietary Cymerus platform technology.
Study NCT05401604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate probiotic beer consumption
Description: Consumption of one can of probiotic beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
Study NCT05401604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Moderate normal beer consumption
Description: Consumption of one can of normal beer per day for 14 days. Blood and fecal samples will be collected at the start and end of the intervention to analyse for immunological biomarkers and gut microbiome.
Study NCT04259060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxocobalamin with Butyrate
Description: In phase 1, patients will take hydroxocobalamin at 1g daily for four weeks. This will be in the form of 1 500mg capsule twice a day. Butyrate will be 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, the dose of hydroxocobalamin will be increased to 2g daily (1g twice a day) for four weeks pending FDA approval. Butyrate will remain at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day. Patients will undergo flexible sigmoidoscopy at baseline and at week four in phase 2.
Study NCT05643638 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is identical to CYP-001, except that it contains no active agent
Study NCT04259060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Butyrate
Description: In phase 1, patients will take 1 placebo capsule twice a day. Butyrate will be taken at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.~In phase 2, patients will take 2 placebo capsules twice a day, along with butyrate at 240 mg daily in a divided dose (120 mg twice daily) which is 5 pills twice a day.
Study NCT05643638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
Study NCT05643638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroids
Description: All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment.
Study NCT06147791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External scrotal drainage
Description: Application of external scrotal drainage during three-component penile prosthesis placement
Study NCT06534437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEN1703
Description: MEN1703 is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Study NCT06534437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glofitamab
Description: Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Study NCT05284656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Pentoxifylline 400 MG and Folic Acid
Description: drugs used to delay progression of chronic kidney disease
Study NCT05284656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: drugs used to delay progression of chronic kidney disease
Study NCT06332729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: universal exercis unit
Description: Universal exercise unit (UEU) consists of system of pulleys, suspensions, belts for supporting and elastic cords. UEU is based on the concept of unloading the body against gravity and to perform movement of weak part of the body. Therapist's hands are free to provide adequate support as required by the patient during exercise training Universal exercise unit, therapy sessions extended are from three to four hours Children and adults have neurological conditions can used. Spider cage is made of metal could be depending on population pediatric or adults. Elastic resistance of cords used to increase strengthen of muscle
Study NCT05284656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 MG
Description: drugs used to delay progression of chronic kidney disease
Study NCT06332729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional electrical stimulation
Description: Functional electrical stimulation (FES) is defined as the electrical stimulation of muscles that have impaired motor control to produce a contraction to obtain functional useful movement
Study NCT05535153 — intervention group
Intervention type: OTHER
Intervention: functional movement screen
Description: The volunteer subjects had to perform the FMS test at the request of the investigator, which is made up of seven movements: the squat, the crossing of the hurdle, the line lunge, the active elevation with the straight leg, a movement concerning the mobility of the shoulders, a rotational stability assessment movement and a core stability assessment movement.
Study NCT05689749 — intervention group
Intervention type: DEVICE
Intervention: Superb Microvascular Imaging (SMI) (Toshiba)
Description: To determine whether SMI has diagnostic value for detecting the inflammatory state in the lacrimal glands in Sjögren's syndrome and whether it has any superiority compared to Power Doppler and Color Doppler modalities.
Study NCT06534437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Study NCT05770739 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Perioperative accelerated rehabilitation surgical measures
Description: To apply accelerated rehabilitation surgery to children with biliary dilatation during perioperative period
Study NCT05770739 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Traditional treatment
Description: To provide traditional perioperative treatment for children with cholangiectasia
Study NCT05623306 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PMT Stereoencephalography (SEEG)
Description: For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
Study NCT05623306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMT Stereoencephalography (SEEG)
Description: For Stage 1 of this study, we will be implanting depth electrodes to record stereoencephalography across a network of brain regions.
Study NCT05623306 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vercise Genus™ Deep Brain Stimulation (DBS) System
Description: For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
Study NCT05623306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise Genus™ Deep Brain Stimulation (DBS) System
Description: For Stages 2 and 3 of this study, we intend to use the DBS system to treat patients with severe symptoms of chronic, treatment-refractory OCD by targeting stimulation to sites that have been determined to have therapeutic benefit during our SEEG Invasive Monitoring phase.
Study NCT05182320 — intervention group
Intervention type: DEVICE
Intervention: OrthoPath
Description: unilateral TKA and THA patients using the BPMpathway rehabilitation sensor system
Study NCT05182320 — intervention group
Intervention type: DEVICE
Intervention: Control
Description: unilateral TKA and THA patients not using the BPMpathway rehabilitation sensor system
Study NCT06209541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (ICBT)
Description: All participants get treatment and are thus included in experimental groups, no matter the randomization result. It consists of eight treatment weeks with weekly support. The treatment format will differ between the four groups, depending on type of treatment content and type of support.
Study NCT06288503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolysed Rice Protein Formula
Description: Infants randomised onto this arm will be taking the hydrolysed rice protein formula, with a minimum prescription of 30% of their energy requirements.
Study NCT06288503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's Milk Based Extensively Hydrolysed Formula
Description: Infants randomised onto this arm will be taking the control product, with a minimum prescription of 30% of their energy requirements.
Study NCT04781192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intra-Venous(IV) once every 28 days (approximately every 4 weeks \[q4w\])
Study NCT04781192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral once per day, Days 1 - 21 every 28 days
Study NCT05068089 — intervention group
Intervention type: PROCEDURE
Intervention: Nissen fundoplication
Description: Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
Study NCT05068089 — intervention group
Intervention type: BIOLOGICAL
Intervention: Enteral nutrition
Description: Type and switch of enteral nutrition formula (tube, PEG, PEJ)
Study NCT06113926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bystander Acknowledgment
Description: The experimenter said That is so messed up that they excluded you in the task. And honestly, I would say it was racist... acknowledgment of the participants experience, ...this shouldn't have happened, and I'm really sorry it did... an apology, and ...I'm going to talk to the primary investigators of the study to figure out how we can make sure that this won't happen to other people a plan of action.
Study NCT04613960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
Study NCT04613960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Placebo treatment
Study NCT05808920 — intervention group
Intervention type: GENETIC
Intervention: Molecular Analyses
Description: Nucleic acid extraction, protein analysis. Tumour tissue, blood and saliva samples collected.
Study NCT06178939 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The entire process is carried out according to Severance Hospital surgical protocols. The patients of control group will receive education from the research team about the importance of nutrition and exercise before and after surgery.
Study NCT06178939 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intervention group
Description: For the intervention group, the entire process is carried out according to the Severance Hospital surgical protocol, and the research team provides education before surgery on the importance of nutrition and exercise before and after surgery. In addition, the cognitive training program developed by Rowan is taught with the goal of performing it for at least 10 hours before the surgery, it is conducted the training program after the surgery.
Study NCT04976751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percutaneous electrical nerve stimulation treatment
Description: Using the percutaneous electrical nerve stimulation instrument to different points of the body
Study NCT05771376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong exercise program
Description: The intervention group will perform a qigong exercise program online (via Zoom video conference) for 12 weeks under the supervision of two physiotherapists. The qigong exercise program had previously been videotaped by the researchers.~qigong exercise program includes: Preparation posture Prop up the sky by two improve trijiao Draw a bow on both sides like shooting a vulture Raise single arm up to regulate spleen Look back to treat five strains and seven impairments Shake the head and wag to expel Heart (Xin)-fire Pull toes with both hands to reinforce the kidney Clench one's fist and glare to increase strength Rise and fall on tiptoe sevan times to treat all diseases Ending posture. Qigong exercises will be performed 45 minutes twice in a week for 12 weeks.
Study NCT05771376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: The home exercise program will include stretching for cervical, thoracic and lumbar flexibility, shoulder girdle, hamstring and erector spinal muscles, and strengthening exercises for abdominal, back, and proximal muscles.~Home exercises will be performed 45 minutes twice in a week for 12 weeks.
Study NCT06261502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD Oral Solution
Description: Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.
Study NCT06261502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.
Study NCT06313775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral orchiectomy
Description: Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
Study NCT06313775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral orchiectomy
Description: Bilateral simple orchiectomy is the surgical removal of both testicles through an incision in the scrotum.
Study NCT05662631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioIntellisense BioSticker
Description: This study uses the BioIntellisense BioSticker for RPM, in combination with the BioSync mobile app on participants' mobile phones for data transmission, augmented by use of the BioHub as a backup transmission device. RPM monitoring of device data is accomplished through use of the AlertWatch software system.~BioSticker System TheBioSticker ® System is an FDA-approved remote monitoring wearable device intended for continuous collection of physiological data in home and healthcare settings. This includes heart rate, respiratory rate, skin temperature, estimated body temperature, frequency of severe cough episodes, activity level, sleep duration, body position, degree of incline while sleeping, step count, step symmetry, step strength, and on/off body times and other symptomatic and biometric data. Data are securely transmitted using AES-CTR 128 bit encryption via wireless connection from the device for storage, review, and further analysis.
Study NCT05630209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate
Description: Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors
Study NCT05630209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin infusion
Study NCT05347771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab is a recombinant DNA-derived humanized IgG4ĸ monoclonal antibody that selectively binds to anti IL-4R monoclonal antibody (mAb).
Study NCT05347771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
Study NCT04898868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cord blood spontaneous drainage
Description: In women allocated to groups of cord blood spontaneous drainage, two clamps will placed at 4 finger breadths from the infant's abdomen and cut between two clamps after delivery of the baby. The clamp on the placental site will be removed and the drainage time and amount of cord blood to a measuring glass will be recored.
Study NCT04898868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord miking
Description: In women allocated to groups of cord milking group, two clamps will placed at 4 finger breadths from the newborn's abdomen and cut between two clamps immediately after delivery of the baby. The clamp on the placental site will be removed, then the umbilical cord will be squeezed several times, 5 seconds between each squeezing, to collect cord blood in a measuring glass. The number of cord milking and the volume of blood collected will be recorded.
Study NCT05795257 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Description: Bronchoalveolar lavage in the middle lobe of the right lung and a mini-bronchoalveolar lavage in the upper and lower lobe of the right lung
Study NCT05605704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study NCT05605704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: atherolive
Description: In each study population(Diabetic), the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Study NCT06263725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restricted dietary protein
Description: Participants will be allocated to 5 week isocaloric restricted protein intake
Study NCT06263725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual diet
Description: Participants will be follow their habitual, high protein intake